Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tenofovir Disoproxil Fumarate

FDA-approved product (tablet, oral), marketed as Tenofovir Disoproxil Fumarate, Viread.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tenofovir Disoproxil Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Infection
  • Liver disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tenofovir Disoproxil Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tenofovir Disoproxil Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

    NCT07797231 · start 2026-09

    Registered record
    Registry ID
    NCT07797231
    Conditions
    Chronic Hepatitis B
    Interventions
    TQA3605 tablets Placebo; TQA3605 tablets; Entecavir dispersible tablets; Tenofovir Disoproxil Fumarate Tablets; Tenofovir Alafenamide Fumarate Tablets; Tenofovir Amibufenamide Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2029-10
    Enrolment
    930

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionTQA3605 tablets Placebo; TQA3605 tablets; Entecavir dispersible tablets; Tenofovir Disoproxil Fumarate Tablets +2 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment

    NCT06221657 · start 2024-02-01

    Registered record
    Registry ID
    NCT06221657
    Conditions
    Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication
    Interventions
    Vemlidy; Virreal
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-02-01
    Completion
    2026-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication
    InterventionVemlidy; Virreal
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

    NCT06707922 · start 2022-03-18

    Registered record
    Registry ID
    NCT06707922
    Conditions
    Chronic Hepatitis B
    Interventions
    Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2022-03-18
    Completion
    2029-07-31
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionPeginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

    NCT05182463 · start 2022-01-08

    Registered record
    Registry ID
    NCT05182463
    Conditions
    Hepatitis B, Chronic
    Interventions
    Peginterferon Alfa-2B; Nucleoside Analogs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-01-08
    Completion
    2029-11-30
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionPeginterferon Alfa-2B; Nucleoside Analogs
    PhasePhase 4
    Registry statusRecruiting

  • Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

    NCT05122754 · start 2021-12-08

    Registered record
    Registry ID
    NCT05122754
    Conditions
    HIV-1-infection
    Interventions
    B/F/TAF; TDF-based triple ART regimen switching to B/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-12-08
    Completion
    2024-04-28
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionB/F/TAF; TDF-based triple ART regimen switching to B/F/TAF
    PhasePhase 4
    Registry statusUnknown

  • Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

    NCT04925752 · start 2021-06-28

    Registered record
    Registry ID
    NCT04925752
    Conditions
    Pre-Exposure Prophylaxis of HIV Infection
    Interventions
    Oral Lenacapavir (LEN); F/TDF; Sub-cutaneous (SC) Lenacapavir (LEN); Placebo SC LEN; PTM F/TDF; PTM Oral LEN; F/TAF (for US participants only)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-06-28
    Completion
    2028-08
    Enrolment
    3,292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-Exposure Prophylaxis of HIV Infection
    InterventionOral Lenacapavir (LEN); F/TDF; Sub-cutaneous (SC) Lenacapavir (LEN); Placebo SC LEN +3 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

    NCT04375800 · start 2021-02-03

    Registered record
    Registry ID
    NCT04375800
    Conditions
    Human Immunodeficiency Virus (HIV) Infection
    Interventions
    Doravirine; 2 NRTIs; DOR/3TC/TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-02-03
    Completion
    2034-04-11
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV) Infection
    InterventionDoravirine; 2 NRTIs; DOR/3TC/TDF
    PhasePhase 2
    Registry statusRecruiting

  • ANCHORS Alcohol & Sexual Health Study: UH3 Project

    NCT04331704 · start 2021-01-12

    Registered record
    Registry ID
    NCT04331704
    Conditions
    Alcohol Use, Unspecified; Substance Use; Sex Behavior
    Interventions
    PrEP acronym (pre-exposure prophylaxis); Initial Web Survey; Interactive Voice Response (IVR) monitoring; Educational material on alcohol and sexual health behavior; Interactive Voice Response (IVR) assessment with personalized information; Personalized information based on web-based survey responses & standardized information
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2021-01-12
    Completion
    2026-06-30
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use, Unspecified; Substance Use; Sex Behavior
    InterventionPrEP acronym (pre-exposure prophylaxis); Initial Web Survey; Interactive Voice Response (IVR) monitoring; Educational material on alcohol and sexual health behavior +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis

    NCT05492565 · start 2020-01-01

    Registered record
    Registry ID
    NCT05492565
    Conditions
    HIV Infection Primary; Hepatitis, Viral, Human; Sexually Transmitted Infections, Excluding HIV and Hepatitis
    Interventions
    Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2020-01-01
    Completion
    2030-12-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection Primary; Hepatitis, Viral, Human; Sexually Transmitted Infections, Excluding HIV and Hepatitis
    InterventionTenofovir Disoproxil Fumarate 300 MG Oral Tablet
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

    NCT04129554 · start 2019-11-06

    Registered record
    Registry ID
    NCT04129554
    Conditions
    Hepatitis B, Chronic
    Interventions
    JNJ-73763989; JNJ-56136379; Placebo for JNJ-73763989; Placebo for JNJ-56136379; Entecavir (ETV) monohydrate; Tenofovir disoproxil fumarate (TDF); Tenofovir alafenamide (TAF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-11-06
    Completion
    2022-06-09
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionJNJ-73763989; JNJ-56136379; Placebo for JNJ-73763989; Placebo for JNJ-56136379 +3 more
    PhasePhase 2
    Registry statusCompleted

  • Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

    NCT04202536 · start 2019-05-29

    Registered record
    Registry ID
    NCT04202536
    Conditions
    Hepatitis B; Besifovir Dipivoxil Maleate; Tenofovir Disoproxil Fumarate
    Interventions
    Besifovir Dipivoxil Maleate; Tenofovir disoproxil fumarate(TDF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-05-29
    Completion
    2021-10
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; Besifovir Dipivoxil Maleate; Tenofovir Disoproxil Fumarate
    InterventionBesifovir Dipivoxil Maleate; Tenofovir disoproxil fumarate(TDF)
    PhasePhase 4
    Registry statusUnknown

  • Optimization of Antiretroviral Therapy

    NCT02935075 · start 2018-03-05

    Registered record
    Registry ID
    NCT02935075
    Conditions
    HIV Infections
    Interventions
    Tenofovir disoproxil fumarate; Lamivudine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-05
    Completion
    2019-08-31
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTenofovir disoproxil fumarate; Lamivudine; Efavirenz
    PhasePhase 4
    Registry statusCompleted

  • Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection

    NCT03425994 · start 2018-02-06

    Registered record
    Registry ID
    NCT03425994
    Conditions
    Chronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
    Interventions
    Elvitegravir/Cobicistat/Emtricitabine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-02-06
    Completion
    2019-10-11
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
    InterventionElvitegravir/Cobicistat/Emtricitabine
    PhaseNot recorded
    Registry statusUnknown

  • A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

    NCT03270969 · start 2018-01-05

    Registered record
    Registry ID
    NCT03270969
    Conditions
    HIV Prevention
    Interventions
    Tenofovir Disoproxil Fumarate/Emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-05
    Completion
    2018-09-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention
    InterventionTenofovir Disoproxil Fumarate/Emtricitabine
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

    NCT03197961 · start 2017-11-17

    Registered record
    Registry ID
    NCT03197961
    Conditions
    HIV/AIDS; Contraception
    Interventions
    tenofovir/emtricitabine; DMPA
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-11-17
    Completion
    2020-12-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS; Contraception
    Interventiontenofovir/emtricitabine; DMPA
    PhaseEarly phase 1
    Registry statusCompleted